1. Introduction
1.1. Market Definition
1.2. Market Segmentation
2. Research Methodology
2.1. Research Data
2.2. Assumptions
3. Executive Summary
3.1. Research Highlights
4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. The Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. Global Cushing’s Syndrome Diagnostic & Treatment Market Analysis, By Diagnostic Test
5.1. Introduction
5.2. Urine & Blood Test
5.3. Saliva Test
5.4. Imaging Tests
5.5. Petrosal Sinus Sampling
6. Global Cushing’s Syndrome Diagnostic & Treatment Market Analysis, By Treatment
6.1. Introduction
6.2. Surgery
6.3. Radiation Therapy
6.4. Medications
7. Global Cushing’s Syndrome Diagnostic & Treatment Market Analysis, By Geography
7.1. Introduction
7.2. North America
7.2.1. United States
7.2.2. Canada
7.2.3. Mexico
7.3. South America
7.3.1. Brazil
7.3.2. Argentina
7.3.3. Others
7.4. Europe
7.4.1. UK
7.4.2. France
7.4.3. Germany
7.4.4. Italy
7.4.5. Others
7.5. Middle East and Africa
7.5.1. Saudi Arabia
7.5.2. UAE
7.5.3. Israel
7.5.4. Others
7.6. Asia Pacific
7.6.1. Japan
7.6.2. China
7.6.3. India
7.6.4. South Korea
7.6.5. Thailand
7.6.6. Taiwan
7.6.7. Indonesia
7.6.8. Others
8. Competitive Environment and Analysis
8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrativeness
8.3. Mergers, Acquisitions, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix
9. Company Profiles
9.1. Novartis
9.2. Corcept Therapeutics Inc.
9.3. StrongBridge Biopharma
9.4. Orphagen Pharmaceuticals Inc.
9.5. HRA Pharma
9.6. Sparrow Pharmaceuticals
9.7. Cyclacel Pharmaceuticals